Global Antiviral Drugs Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Antiviral Drugs Market was valued at $66.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 4.2% CAGR, to an estimated market size of $81.7 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global antiviral drugs market comprises pharmaceutical agents specifically formulated to treat viral infections by inhibiting the development and replication of viruses within a host. The scope includes therapies for chronic conditions such as HIV/AIDS and Hepatitis, as well as acute infections like influenza, herpes simplex, and respiratory syncytial virus (RSV), while excluding vaccines and non-specific immune boosters.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Antiviral Drugs Market in the period 2025-30:
- The increasing global burden of chronic viral infections, particularly HIV and Hepatitis B, remains the primary driver for long-term medication demand.
- Significant pharmaceutical investment is shifting toward next-generation antivirals and broad-spectrum therapies to address viral mutations.
- The integration of Artificial Intelligence is accelerating the drug discovery process and improving the efficiency of clinical trials for novel molecules.
- There is a growing clinical preference for long-acting therapies and combination treatments to enhance patient adherence and reduce drug resistance.
- Heightened focus on pandemic preparedness by governments is driving the stockpiling of antivirals and the development of rapid-response platforms.
- The expansion of healthcare infrastructure and diagnostic capabilities in emerging markets is unlocking significant untapped patient populations.
- Regulatory bodies are increasingly providing fast-track approvals for antiviral drugs targeting high-priority or emerging infectious threats.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- HIV/AIDS
- Hepatitis (B and C)
- Influenza
- Other Indications